Relation between vesical function and gait in people with human T-Lymphotropic virus type 1
DOI:
https://doi.org/10.17765/1983-1870.2018v11n2p213-221Keywords:
Spastic paraparesis, International functionality classification, Inability and health, Physiotherapy.Abstract
Current analytic, observational and transversal study correlates bladder dysfunction and the need for gait aid in people with human T-lymphotropic virus type 1. Investigation was undertaken with 16 patients of both genders, with a definite diagnosis for Tropical Spastic Paraparesis/Mielopathy, associated with HTLV-1 (PET/MAH), evaluated by the Spastic Paraplegia Rating Scale (SPRS) and characterized as to help degree in gait by devices employed during walking. Finding were codified by the International Classification for Functionality, Disability and Health (ICF). Findings related to vesical function were converted into component body functions; in the case of gait aid, they were converted into activity and participation. G test (adherence), chi-square and Spearman´s correlation for statistical analysis (p?0.05) were employed. Most patients had a slight condition for vesical function (b6202.1), with no (d465.0) or only moderate difficulty (d465.2) for gait aid. There was a correlation (p=0.009) between gait aid and bladder function. ICF codes revealed that the greatest the difficulty in locomotion, the biggest the issue in bladder function.Downloads
References
Bangham CRM, Araujo A, Yamano Y, Taylor GP. HTLV-1-associated myelopathy/tropical spastic paraparesis. Nat Rev Dis Primers 2015;1:15012.
Cabral F, Arruda LB, de Araújo ML, Montanheiro P, Smid J, de Oliveira AC, et al. Detection of human T-cell lymphotropic virus type 1 in plasma samples. Virus Res 2012;163(1):87–90.
Morgan O. HTLV-1 associated myelopathy/tropical spastic paraparesis: how far have we come? West Indian Med J 2011;60(5):505–12.
Oliére S, Douville R, Sze A, Belgnaoui SM, Hiscott J. Modulation of innate immune responses during human T-cell leukemia virus (HTLV-1) pathogenesis. Cytokine Growth Factor Rev 2011;22(4):197–210.
Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci 2011;102(2): 295–301.
Romanelli LC, Carameli P, Proietti AB. Human T-cell lymphotropic virus type 1 (HTLV-1): when to suspect infection? Rev Assoc Med Bras. 2010;56(3):340–7.
Catalan-Soares B, Carneiro-Proietti AB, Proietti FA. Heterogeneous geographic distribution of human T-cell lymphotropic viruses I and II (HTLV-I/II): serological screening prevalence rates in blood donors from large urban areas in Brazil. Cad Saude Publica. 2005;21(3):926-31.
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front. Microbiol. 2012;3:1-23.
Lairmore MD, Haines R, Anupam R. Mechanisms of human T-lymphotropic virus type 1 transmission and disease. Curr Opin Virol 2012;2(4):474–81.
Araujo AQ, Silva MT. The HTLV-1 neurological complex. Lancet Neurol 2006; 5(12):1068–76.
Cooper SA, van der Loeff MS, Taylor GP. The neurology of HTLV-1 infection. Pract Neurol 2009;9(1):16–26.
Journo C, Mahieux R. HTLV-1 and innate immunity. Viruses 2011;3(8):1374–94.
Nakamura T. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol 2009;47(2):182–94
Puccioni-Sohler M, Gasparetto E, Cabral-Castro MJ, Slatter C, Vidal CM, Cortes RD, et al. HAM/TSP: association between whitematter lesions onmagnetic resonance imaging, clinical and cerebrospinal fluid findings. Arq Neuropsiquiatr 2012;70(4):246–51.
Matsuura E, Yamano Y, Jacobson S. Neuroimmunity of HTLV-I infection. J Neuroimmune Pharmacol 2010;5(3):310–25.
Gonçalves DU, Proietti FA, Ribas JG, Araújo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases. Clin Microbiol Rev 2010;23(3):577–89.
Fairbairn K, May K, Yang Y, Balasundar S, Hefford C, Abbott JH. Mapping patient-specifi c functional scale (PSFS) items to the international classifi cation of functioning, disability and health (ICF). Phys Ther. 2012;92(2):310-317.
De Castro-Costa CM, Araújo AQ, Barreto MM, Takayanagui OM, Sohler MP, da Silva EL et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses 2006;22(10):931–935.
Schüle R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, et al. The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology. 2006; 67(3):430-4.
Grassi MF, Olavarria VN, Kruschewsky R de A, Mascarenhas RE, Dourado I, Correia LC, et al. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients according to new diagnostic criteria of HAM/TSP. J Med Virol. 2011;83(7):1269-74.
Netto EC, Brites C. Characteristics of Chronic Pain and Its Impact on Quality of Life of Patients with HTLV-1-associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). Clin J Pain. 2011;27(2):131-5.
Romanelli LC, Caramelli P, Proietti AB. Human T cell lymphotropic virus (HTLV-1): when to suspect infection? Rev Assoc Med Bras. 2010;56(3):340-7.
Tanajura D, Santos AM, Castro N, Siqueira I, Carvalho EM, Glesby MJ. Neurological symptoms and signs in HTLV-1 patients with overactive bladder syndrome. Arq Neuropsiquiatr. 2012;70(4):252–256.
Siqueira IC, Muniz AL, Oliveira P, Carvalho DC, Orge GO, Castro N, Bittencourt VC et al. Manisfestações Clínicas em pacientes infectados pelo vírus linfotrópico de células T humanas (HTLV). Gazeta Médica da Bahia. 2009;79:(1):61-67.
Andrade RCP. Fisioterapia Pélvica em pacientes infectados pelo vírus Linfotrópico das células T humano do tipo 1 (HTLV -1) com disfunção vésico-uretral [Tese] 128f. Salvador: Universidade Federal da Bahia; 2015.
Fuzii HT, Dias GA, Barros RJS, Falcão LFM, Quaresma JAS. Immunopathogenesis of HTLV-1-assoaciated myelopathy/tropical spastic paraparesis (HAM/TSP). Life Science.2014;104:10-4.
Nascimento AG, Cardoso EA, Gonçalves EBS, Araujo MV, Muniz MAS. Estratégias fisioterapêuticas no tratamento da paraparesia espástica tropical/mielopatia associada ao HTLV-1 (PET/MAH). Fisioter Ser. 2010;3:164-8.
Dias GAS, Yoshikawa GT, Koyama RV, Fujihara S, Martins LC, Medeiros R, et al. Neurological manifestations in individuals with HTLV-1-associated myelopathy/tropical spastic paraparesis in the Amazon. Spinal Cord. 2016;54(2):154-157.
Lannes P, Neves MAO, Machado DCD, Miana LC, Silva JG, Bastos VHV. Paraparesia Espástica Tropical - Mielopatia associada ao vírus HTLV- I: possíveis estratégias cinesioterapêuticas para a melhora dos padrões de marcha em portadores sintomáticos. Rev neuroc. 2006;14(3):153-160.
Sá KN, Macêdo MC, Andrade RP, Mendes SD, Martins JV, Baptista AF. Physiotherapy for human T-lymphotropic virus 1-associated myelopathy: review of the literature and future perspectives. J Multidisciplinary Healthcare. 2015;8:117-25.
Dias GAS, Sousa RCM, Gomes LF, Caldas CAM, Nassiri R, Quaresma JAS et al. Correlation between clinical symptoms and peripheral immune response in HAM/TSP. Microbial Pathogenesis. 2016;92:72-5.
Gascón MR, Capitão CG, Casseb J, Nogueira-Martins MC, Smid J, Oliveira AC. Prevalence of anxiety, depression and quality of life in HTLV-1 infected patients. Braz J Infect Dis. 2011;15(6):578–582.
Downloads
Published
How to Cite
Issue
Section
License
A submissão de originais para a revista Saúde e Pesquisa implica na transferência da Carta Concessão de Direitos Autorais, pelos autores, dos direitos de publicação digital para a revista após serem informados do aceite de publicação.A Secretaria Editorial irá fornecer da um modelo de Carta de Concessão de Direitos Autorais, indicando o cumprimento integral de princípios éticos e legislação específica. Os direitos autorais dos artigos publicados nesta revista são de direito do autor, com direitos da revista sobre a primeira publicação. Os autores somente poderão utilizar os mesmos resultados em outras publicações, indicando claramente a revista Saúde e Pesquisa como o meio da publicação original. Em virtude de tratar-se de um periódico de acesso aberto, é permitido o uso gratuito dos artigos, principalmente em aplicações educacionais e científicas, desde que citada a fonte. A Saúde e Pesquisa adota a licença Creative Commons Attribution 4.0 International.
A revista se reserva o direito de efetuar, nos originais, alterações de ordem normativa, ortográfica e gramatical, com vistas a manter o padrão culto da língua e a credibilidade do veículo. Respeitará, no entanto, o estilo de escrever dos autores. Alterações, correções ou sugestões de ordem conceitual serão encaminhadas aos autores, quando necessário. Nesses casos, os artigos, depois de adequados, deverão ser submetidos a nova apreciação. As opiniões emitidas pelos autores dos artigos são de sua exclusiva responsabilidade.